

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **CHANGE OF EXECUTIVE DIRECTORS; AND CHANGE IN COMPOSITION OF BOARD COMMITTEE**

The Board hereby announces that, with effect from 18 September 2025, (1) Mdm. Deng Rong has resigned as an executive Director and a member of the Executive Committee; and (2) Mr. Liu Changan has been appointed as an executive Director and a member of the Executive Committee.

### **RESIGNATION OF EXECUTIVE DIRECTOR AND MEMBER OF THE EXECUTIVE COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that, with effect from 18 September 2025, Mdm. Deng Rong (“**Mdm. Deng**”) has resigned as an executive Director and a member of the executive committee of the Company (the “**Executive Committee**”) due to other work arrangements. Following her resignation from the above positions, Mdm. Deng continues to serve as the chief financial officer of the Company. Mdm. Deng has confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Mdm. Deng for her invaluable contributions to the Board during her tenure of directorship.

### **APPOINTMENT OF EXECUTIVE DIRECTOR AND MEMBER OF THE EXECUTIVE COMMITTEE**

The Board announces that, with effect from 18 September 2025, Mr. Liu Changan (“**Mr. Liu**”) has been appointed as an executive Director and a member of the Executive Committee.

**Mr. Liu Changan**, aged 52, has been appointed as an executive Director and a member of the Executive Committee on 18 September 2025. He has been a director of China Resources Pharmaceutical Holdings Company Limited, a subsidiary of the Company, since October 2024. Mr. Liu served in the Agricultural Committee and Agricultural Bureau of the Beijing Municipal Party Committee from January 2023 to July 2023. Mr. Liu graduated from the National Defense University of the People's Liberation Army in January 2004 with a Master's degree.

There is no service contract entered into between Mr. Liu and the Company for his position as an executive Director. He has no fixed term of service with the Company, but he will be subject to retirement by rotation and re-election at annual general meetings of the Company pursuant to the articles of association of the Company. Mr. Liu shall hold office until the next annual general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting. Thereafter, Mr. Liu shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mr. Liu will not receive any director's emolument from the Company. He is entitled to pre-tax basic monthly salary of RMB70,100 from the Company based on his position, duties and responsibilities, as well as discretionary bonus and term-wide incentives based on the results performance of the Company and himself.

As at the date of this announcement, Mr. Liu does not have any interests in the shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Liu have confirmed that (i) he has and had no other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not currently hold any other position with the Company or any of its subsidiaries; (iii) he has not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board takes this opportunity to extend a warm welcome to Mr. Liu for the appointments.

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Mr. Bai Xiaosong**  
*Chairman*

PRC, 18 September 2025

*As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.*